

(I)

its pharmaceutically acceptable salts, enantiomers, diastereomers, or N-oxides, wherein **Y** is O or S; **Q, Z** and **Z'** are independently CH; X is CH or N; **m**=0-3; **n**=0-4; $\mathbf{R_1}$, $\mathbf{R_2}$ are independently selected from: H, F, Cl, Br, OCH_3, OC_2H_5, OCH_2CF_3, SCF_3, CH_3, C_2H_5, CF_3, isopropyloxy, and cyclopropyl; and R_3, R_4 and R_5 are independently H, C_{1-3} alkyl, substituted or unsubstituted phenyl, [or a 5-membered spiro ring,] except when R_1- R_5 are H; m is 0; n is 2; Q is CH; X is N; Y is O; Z and Z' are [N] CH, and except when R_1 is H; R_2 is H; Cl or CH_3; R_3- R_5 are H; m is 0; n is 1; X is N; Y is O; Z and Z' are CH, which comprises reacting a compound having the structure of Formula VI'



(VI')

with a compound having the structure of Formula V in pyridine at reflux temperature followed by reflux in the presence of acetic anhydride



(V)

thereby to produce the compound of Formula I.

45. [The] A method [of claim 44] for [producing] making a compound having the structure of Formula II



(II)

[wherein n, X, Z, Z' and R_1, R_2 and R_3 are as defined for Formula I and m' = 1,4,] its pharmaceutically acceptable salts, enantiomers, diasteromers, or N-oxides, wherein X is CH or N; Z and Z' are independently CH; n= 0-4; m' =1-4; R_1, R_2 are independently selected from: H, F, CL, Br, OCH_3, OC_2H_5, OCH_2CF_3, SCF_3, CH_3, isopropyloxy, and cyclopropyl; and R_3 is independently H, C_{1-3} alkyl substituted or unsubstituted phenyl, except when R_1-R_3 are H; n is 2; X is N; Z and Z' are CH, and except when R_1 is H; R_2 is H, Cl or CH_3; R_3 is H; n is 1; X is N; Z and Z' are CH which comprises reacting a compound having the structure of Formula VI



(VI)

with [said] a compound having the structure of Formula V.



(V)